CEL-SCI Corporation (NYSE AMEX: CVM) announced today that, following completion of a successful site initiation visit, the New Jersey Medical School and Veterans Affairs Medical Center is ready to begin immediate enrollment of qualified patients that desire to participate in its Phase III clinical trial of Multikine®, the Company’s flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.
